Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis

Autor: Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, Muram, D, Bradley, J, De Bono, S, Rooney, T, Tanaka, Y, Faraawi, R

Publikováno v: 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20170906-20170909; Stuttgart; DOCRA.28 /20170904/

Background: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA). The objective of this analysis was to evaluate efficacy and safety in pts from RA-BEAM who switched f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a5be0180643c157780129be891144b3
https://doi.org/10.3899/jrheum.170256

A0078 - FGFR testing from matched tissue and urine samples from pilot cohort the prospective Real World clinico-pathological register trial „BRIDGister

Autor: Wirtz, R., Watts, R., Kellner, R., Ortmann, R., Horns, T., Enderle, D., Meyer, L., Noerholm, M., Morken, M., Veltrup, E., Hake, R., Eidt, S., Roggisch, J., Koch, S., Ecke, T.H.

Publikováno v: In European Urology February 2022 81 Supplement 1:S118-S118

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis

Autor: Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, Muram, D, Bradley, J, de Bono, S, Rooney, T, Tanaka, Y

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::6f6af8b034fe5a9e40e6c0ac0261033f
https://ora.ox.ac.uk/objects/uuid:16fcb858-2175-4457-92f7-d2651eba5269

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

EFFICACY AND SAFETY OF TABALUMAB, AN ANTI-B CELL ACTIVATING FACTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO TNF-ALPHA INHIBITORS: RESULTS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY

Autor: Schiff, M., Combe, B., Dorner, T., Kremer, J.M., Huizinga, T.W., Veenhuizen, M., Gill, A., Zou, H., Komocsar, W., Berclaz, P.Y., Ortmann, R., Lee, C.

Publikováno v: Annals of the Rheumatic Diseases, 73, 952-953

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3a6a1776ff4c9993a6a03455fe6ef5c8
https://hdl.handle.net/1887/101707